Evolving treatment goals for migraine disease

At EAN 2022, Cristina Tassorelli, Professor of Neurology, University of Pavia, Italy, discussed how treatment goals are evolving and improving due to an increasing number of targeted therapies for migraine. In the past, the benchmark of efficacy was 50% reduction in number of migraine days per month and alternative drugs were offered if this goal was not met. With current, migraine-specific, medication, migraine days can be reduced by 75% per month for at least some patients, with a wider treatment choice if this goal is not met.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country